ENTECH SACA (ALESE.PA) Stock Fundamental Analysis

EPA:ALESE • FR0014004362

9.73 EUR
-0.37 (-3.66%)
Last: Feb 26, 2026, 07:00 PM
Fundamental Rating

4

ALESE gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 44 industry peers in the Construction & Engineering industry. While ALESE seems to be doing ok healthwise, there are quite some concerns on its profitability. ALESE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ALESE has reported negative net income.
  • ALESE had a positive operating cash flow in the past year.
  • In the past 5 years ALESE reported 4 times negative net income.
  • ALESE had a negative operating cash flow in each of the past 5 years.
ALESE.PA Yearly Net Income VS EBIT VS OCF VS FCFALESE.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

  • With a Return On Assets value of -3.88%, ALESE is not doing good in the industry: 95.45% of the companies in the same industry are doing better.
  • ALESE's Return On Equity of -11.31% is on the low side compared to the rest of the industry. ALESE is outperformed by 90.91% of its industry peers.
Industry RankSector Rank
ROA -3.88%
ROE -11.31%
ROIC N/A
ROA(3y)-2.34%
ROA(5y)-0.87%
ROE(3y)-4.85%
ROE(5y)-2.97%
ROIC(3y)N/A
ROIC(5y)N/A
ALESE.PA Yearly ROA, ROE, ROICALESE.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

  • Looking at the Gross Margin, with a value of 42.82%, ALESE is in line with its industry, outperforming 54.55% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ALESE has declined.
  • ALESE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.07%
GM growth 5YN/A
ALESE.PA Yearly Profit, Operating, Gross MarginsALESE.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 40 60

6

2. Health

2.1 Basic Checks

  • ALESE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ALESE has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, ALESE has a worse debt to assets ratio.
ALESE.PA Yearly Shares OutstandingALESE.PA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M
ALESE.PA Yearly Total Debt VS Total AssetsALESE.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • ALESE has an Altman-Z score of 2.62. This is not the best score and indicates that ALESE is in the grey zone with still only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.62, ALESE is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
  • The Debt to FCF ratio of ALESE is 1.80, which is an excellent value as it means it would take ALESE, only 1.80 years of fcf income to pay off all of its debts.
  • ALESE has a Debt to FCF ratio of 1.80. This is in the better half of the industry: ALESE outperforms 79.55% of its industry peers.
  • ALESE has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.27, ALESE is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 1.8
Altman-Z 2.62
ROIC/WACCN/A
WACC7.84%
ALESE.PA Yearly LT Debt VS Equity VS FCFALESE.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • ALESE has a Current Ratio of 1.57. This is a normal value and indicates that ALESE is financially healthy and should not expect problems in meeting its short term obligations.
  • ALESE has a Current ratio of 1.57. This is amongst the best in the industry. ALESE outperforms 84.09% of its industry peers.
  • ALESE has a Quick Ratio of 1.51. This is a normal value and indicates that ALESE is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.51, ALESE belongs to the top of the industry, outperforming 88.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.51
ALESE.PA Yearly Current Assets VS Current LiabilitesALESE.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

7

3. Growth

3.1 Past

  • The earnings per share for ALESE have decreased strongly by -294.30% in the last year.
  • ALESE shows a strong growth in Revenue. In the last year, the Revenue has grown by 32.45%.
  • Measured over the past years, ALESE shows a very strong growth in Revenue. The Revenue has been growing by 68.95% on average per year.
EPS 1Y (TTM)-294.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.21%
Revenue 1Y (TTM)32.45%
Revenue growth 3Y68.95%
Revenue growth 5YN/A
Sales Q2Q%56.95%

3.2 Future

  • Based on estimates for the next years, ALESE will show a very strong growth in Earnings Per Share. The EPS will grow by 116.80% on average per year.
  • ALESE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.92% yearly.
EPS Next Y142.86%
EPS Next 2Y124.67%
EPS Next 3Y116.8%
EPS Next 5YN/A
Revenue Next Year38.3%
Revenue Next 2Y49.35%
Revenue Next 3Y47.95%
Revenue Next 5Y37.92%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALESE.PA Yearly Revenue VS EstimatesALESE.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
ALESE.PA Yearly EPS VS EstimatesALESE.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 0.4 0.6 0.8

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALESE. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 29.52, ALESE can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, ALESE is valued a bit more expensive than the industry average as 79.55% of the companies are valued more cheaply.
  • ALESE is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 29.52
ALESE.PA Price Earnings VS Forward Price EarningsALESE.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, ALESE is valued a bit cheaper than 68.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.85
EV/EBITDA N/A
ALESE.PA Per share dataALESE.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ALESE's earnings are expected to grow with 116.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y124.67%
EPS Next 3Y116.8%

0

5. Dividend

5.1 Amount

  • No dividends for ALESE!.
Industry RankSector Rank
Dividend Yield 0%

ENTECH SACA

EPA:ALESE (2/26/2026, 7:00:00 PM)

9.73

-0.37 (-3.66%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners11.25%
Inst Owner ChangeN/A
Ins Owners63.76%
Ins Owner ChangeN/A
Market Cap143.03M
Revenue(TTM)45.47M
Net Income(TTM)-2.92M
Analysts86
Price Target12.14 (24.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)50%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 29.52
P/S 3.15
P/FCF 10.85
P/OCF 10.08
P/B 5.54
P/tB 7.28
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)0.33
Fwd EY3.39%
FCF(TTM)0.9
FCFY9.21%
OCF(TTM)0.96
OCFY9.92%
SpS3.09
BVpS1.76
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.88%
ROE -11.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.82%
FCFM 28.98%
ROA(3y)-2.34%
ROA(5y)-0.87%
ROE(3y)-4.85%
ROE(5y)-2.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.07%
GM growth 5YN/A
F-Score3
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 1.8
Debt/EBITDA N/A
Cap/Depr -3048.48%
Cap/Sales 2.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.51
Altman-Z 2.62
F-Score3
WACC7.84%
ROIC/WACCN/A
Cap/Depr(3y)285.26%
Cap/Depr(5y)212.15%
Cap/Sales(3y)7.1%
Cap/Sales(5y)9.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-294.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.21%
EPS Next Y142.86%
EPS Next 2Y124.67%
EPS Next 3Y116.8%
EPS Next 5YN/A
Revenue 1Y (TTM)32.45%
Revenue growth 3Y68.95%
Revenue growth 5YN/A
Sales Q2Q%56.95%
Revenue Next Year38.3%
Revenue Next 2Y49.35%
Revenue Next 3Y47.95%
Revenue Next 5Y37.92%
EBIT growth 1Y-189.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year291.46%
EBIT Next 3Y158.85%
EBIT Next 5Y100.56%
FCF growth 1Y230.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y258.99%
OCF growth 3YN/A
OCF growth 5YN/A

ENTECH SACA / ALESE.PA FAQ

What is the fundamental rating for ALESE stock?

ChartMill assigns a fundamental rating of 4 / 10 to ALESE.PA.


What is the valuation status for ALESE stock?

ChartMill assigns a valuation rating of 3 / 10 to ENTECH SACA (ALESE.PA). This can be considered as Overvalued.


What is the profitability of ALESE stock?

ENTECH SACA (ALESE.PA) has a profitability rating of 1 / 10.


How financially healthy is ENTECH SACA?

The financial health rating of ENTECH SACA (ALESE.PA) is 6 / 10.